HC Wainwright Predicts Reduced Earnings for Bausch + Lomb

Bausch + Lomb Co. (NYSE:BLCO) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Bausch + Lomb in a note issued to investors on Friday, February 21st. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.15 per share for the quarter, down from their previous estimate of $0.20. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.76 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.18 EPS and Q4 2025 earnings at $0.20 EPS.

Several other equities analysts have also issued reports on BLCO. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a report on Thursday. Citigroup downgraded Bausch + Lomb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $22.00 in a research note on Wednesday, December 11th. Wells Fargo & Company decreased their price target on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, January 16th. Stifel Nicolaus dropped their price target on Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada cut their price objective on shares of Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Bausch + Lomb currently has a consensus rating of “Hold” and a consensus target price of $19.83.

Bausch + Lomb Trading Down 0.9 %

NYSE BLCO opened at $15.75 on Monday. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69. The company has a 50 day moving average price of $17.36 and a 200 day moving average price of $18.17. The company has a quick ratio of 0.95, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The firm has a market cap of $5.55 billion, a PE ratio of -17.30, a price-to-earnings-growth ratio of 2.20 and a beta of 0.46.

Bausch + Lomb (NYSE:BLCO) last announced its earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the previous year, the company posted $0.24 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis.

Institutional Investors Weigh In On Bausch + Lomb

Large investors have recently bought and sold shares of the company. Alpine Global Management LLC acquired a new stake in Bausch + Lomb during the 4th quarter valued at approximately $181,000. Tang Capital Management LLC raised its holdings in shares of Bausch + Lomb by 28.6% during the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company’s stock worth $8,127,000 after purchasing an additional 100,000 shares during the last quarter. Polar Asset Management Partners Inc. lifted its position in Bausch + Lomb by 120.4% during the fourth quarter. Polar Asset Management Partners Inc. now owns 33,062 shares of the company’s stock valued at $597,000 after purchasing an additional 18,062 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Bausch + Lomb by 34.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,460 shares of the company’s stock valued at $947,000 after purchasing an additional 13,460 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in Bausch + Lomb during the 4th quarter worth about $735,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.